Table 1.
Demographic, clinical and electrocardiographic findings in the study cohort
| Whole Cohort (N = 52) | Conduction Abnormality Positive (N = 31) | Conduction Abnormality Negative (N = 21) | P value | |
|---|---|---|---|---|
| Demographic data | ||||
| Age, years | 41.2 ± 13.9 | 43.7 ± 11.9 | 37.4 ± 15.9 | 0.129 |
| Male gender, N (%) | 20 (38) | 11 (35) | 9 (43) | 0.772 |
| BMI, kg/m2 | 25.5 ± 5.8 | 25.8 ± 6.2 | 24.9 ± 5.1 | 0.618 |
| DM, N (%) | 5 (10) | 4 (13) | 1 (5) | 0.637 |
| HTN, N (%) | 3 (6) | 1 (3) | 2 (9) | 0.558 |
| Smoking, N (%) | 2 (4) | 2 (6) | 0 (0) | 0.494 |
| HLP, N (%) | 5 (10) | 4 (13) | 1 (5) | 0.637 |
| History of CAD, N (%) | 1 (2) | 1 (3) | 0 (0) | 0.999 |
| BB, N (%) | 4 (8) | 3 (10) | 1 (5) | 0.639 |
| ACE-i, N (%) | 3 (6) | 2 (6) | 1 (5) | 0.999 |
| ARB, N (%) | 1 (2) | 1 (3) | 0 (0) | 0.999 |
| MCRA, N (%) | 4 (8) | 4 (13) | 0 (0) | 0.138 |
| Statin, N (%) | 6 (11) | 4 (13) | 2 (9) | 0.999 |
| Myotonic Muscular Dystrophy Characteristics | ||||
| Age of onset, years | 28.8 ± 15.5 | 28.2 ± 17.1 | 29.6 ± 13.1 | 0.749 |
| Disease length, years | 12.4 ± 12.7 | 15.5 ± 14.8 | 7.8 ± 6.9 | 0.015* |
| CTG Repeats | 500 (200–1163) | 280 (142–772) | 575 (450–1450) | 0.137 |
| MIRS scale | 3 (3–4) | 3 (3–4) | 3 (2–3) | 0.041* |
| Clinical data | ||||
| SBP, mmHg | 126 ± 18 | 125 ± 18 | 126 ± 19 | 0.798 |
| DBP, mmHg | 74 ± 10 | 74 ± 11 | 75 ± 8 | 0.733 |
| HR, bpm | 74 ± 14 | 74 ± 16 | 75 ± 12 | 0.793 |
| NYHA class | 2 (1–2) | 2 (1–2) | 1 (1–2) | 0.900 |
| Hematocrit, % | 42.1 ± 3.8 | 42.3 ± 3.4 | 41.7 ± 4.4 | 0.592 |
| Electrocardiographic Data | ||||
| PR, ms | 199 ± 47 | 223 ± 48 | 165 ± 16 | < 0.001 |
| QRS, ms | 103 ± 20 | 111 ± 22 | 94 ± 11 | 0.001 |
| QT, ms | 404 ± 42 | 412 ± 47 | 392 ± 31 | 0.070 |
| QTc, ms | 428 ± 32 | 431 ± 38 | 423 ± 23 | 0.359 |
| Frontal QRS-T angle | 41 ± 41 | 45 ± 44 | 36 ± 36 | 0.447 |
| LVH-Cornell, N (%) | 13 (25) | 11 (35) | 2 (9) | 0.050 |
Data are presented as mean ± SD, N (%), or median (interquartile range). *p < 0.05 considered significant. BMI body mass index, DM diabetes mellitus, HLP hyperlipidemia, CAD coronary artery disease, BB beta-blockers, ACE-i Angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blockers, MCRA aldosterone antagonists, MIRS Muscular Impairment Rating Scale, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, NYHA New York Heart Association class, LVH left ventricular hypertrophy